Molecular Formula | C21H26N2O5 |
Molar Mass | 386.44 |
Density | 1.250 |
Boling Point | 649.0±55.0 °C(Predicted) |
pKa | 9.42±0.20(Predicted) |
Use | Odarterol has a nearly full-effect β2-receptor agonism (the semi-maximum effect concentration is 0.1nM, and the affinity internal activity with isoprenaline is 88%). Otarterol has different effects on different β-adrenergic receptors. It has a complete agonist effect on β2-receptors, while it is a partial agonist to β1-adrenergic receptors. |
Odarterol (Olodaterol) is a new type of selective fast-acting β2-adrenergic receptor agonist. This product can bind to β2 receptors to increase the level of intracellular cAMP, which in turn causes protein kinase A The activation and phosphorylation of other related targets finally achieve the effect of dilating the trachea. Odarol has high selectivity for β2-adrenergic receptors (referred to as β2-receptors) and has rapid onset of effect, long half-life, more than 12h, can maintain 24h of bronchodilation.
Synthesis method of odaterol:
platinum dioxide used in this method is more expensive, and the bromination reaction yield is low (74%). Compound 2 is protected by benzylation, nitration, nitro reduction, acyl chlorination, intramolecular condensation, oxidation, esterification, condensation and debenzyl. The target product obtained by this method is the racemate of Odarterol, which is not a single configuration target product.